BACKGROUND: Even though patients with class 3 obesity (body mass index ≥ 40 kg/m(2)) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospective clinical trials are lacking. METHODS: In a post hoc analysis of a clinical trial, we compared patients with class 3 obesity with patients with class 1/2 obesity. RESULTS AND CONCLUSIONS: Blood pressure control in class 3 obesity was less likely to be achieved with hydrochlorothiazide monotherapy. While addition of amlodipine, irbesartan, or aliskiren to hydrochlorothiazide improved the blood pressure response, amlodipine was less effective and induced peripheral edema in 19% of patients with class 3 obesity.
BACKGROUND: Even though patients with class 3 obesity (body mass index ≥ 40 kg/m(2)) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospective clinical trials are lacking. METHODS: In a post hoc analysis of a clinical trial, we compared patients with class 3 obesity with patients with class 1/2 obesity. RESULTS AND CONCLUSIONS: Blood pressure control in class 3 obesity was less likely to be achieved with hydrochlorothiazide monotherapy. While addition of amlodipine, irbesartan, or aliskiren to hydrochlorothiazide improved the blood pressure response, amlodipine was less effective and induced peripheral edema in 19% of patients with class 3 obesity.
Authors: William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh Journal: J Clin Hypertens (Greenwich) Date: 2002 Nov-Dec Impact factor: 3.738
Authors: Kathleen McTigue; Joseph C Larson; Alice Valoski; Greg Burke; Jane Kotchen; Cora E Lewis; Marcia L Stefanick; Linda Van Horn; Lewis Kuller Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: M S Rumantir; M Vaz; G L Jennings; G Collier; D M Kaye; D R Seals; G H Wiesner; H P Brunner-La Rocca; M D Esler Journal: J Hypertens Date: 1999-08 Impact factor: 4.844
Authors: Henry T Stelfox; Sofia B Ahmed; Rodrigo A Ribeiro; Elise M Gettings; Eugene Pomerantsev; Ulrich Schmidt Journal: Crit Care Med Date: 2006-04 Impact factor: 7.598
Authors: Vineet Bhan; Raymond T Yan; Lawrence A Leiter; David H Fitchett; Anatoly Langer; Eva Lonn; Mary Tan; Stewart Silagy; Shaun G Goodman; Andrew T Yan Journal: Am J Cardiol Date: 2010-11-01 Impact factor: 2.778